PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.
Colorectal Cancer|RAS Mutation|Colorectal Neoplasms|Microsatellite Stable Colorectal Carcinoma
DRUG: oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
ORR, The proportion of patients with a confirmed complete response or partial response, up to 3 years
PFS, The time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first, up to 3 years|OS, The time from randomization to death from any reason, up to 3 years|DCR, The proportion of patients with a best overall response of confirmed complete or partial response, or stable disease (CR+ PR + SD), up to 3 years|Safety and tolerability by incidence, severity and outcome of adverse events, Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0, up to 3 years
This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.